Health related quality of life trajectories of patients in opioid substitution treatment

Nosyk, Bohdan; Guh, Daphne; Sun, Huiying; Oviedo‐Joekes, Eugenia; Brissette, Suzanne; Marsh, David C.; Schechter, Martin T.; Anis, Aslam H.

doi:10.1016/j.drugalcdep.2011.04.003

Cited by 56 publications

(69 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, some of the findings for the EQ-5D-5L are similar to the ones from other studies on EQ-5D-3L. Research has shown that improvements in participants receiving opiate substitution treatment are commonly evident in the dimensions of pain/discomfort (33.2%), anxiety/depression (31.5%), and usual activities (30.3%) [36]. These dimensions were also the most responsive in this study with 43.2%, 41.9%, and 32.4% of participants reporting improvements in the three dimensions respectively during the first three months of the trial.…”

Section: Discussionsupporting

confidence: 78%

“…Despite the positive emerging evidence for the psychometric properties of the ICECAP-A [32][33][34][35] and EQ-5D-5L [6][7][8][9], no evidence is yet available for the context of opiate dependence. Even though some supporting evidence for the EQ-5D-3L and other similar health-focused measures exists for this context [36][37][38][39], such measures are used with caution in economic evaluations [40,41]. This study aims to explore the psychometric performance of the ICECAP-A and EQ-5D-5L in a sample of heroin users in opiate substitution treatment.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Measuring Health and Broader Well-Being Benefits in the Context of Opiate Dependence: The Psychometric Performance of the ICECAP-A and the EQ-5D-5L

et al. 2016

View full text Add to dashboard Cite

2 Key points What is already known about the topic? Treatments for substance use disorders aim at improving health and, most importantly, broader wellbeing. Health-related measures of quality of life may not adequately capture the broader wellbeing benefits associated with such complex interventions. Comprehensive evidence on the validity and responsiveness of these measures in this context is lacking. When broader capability-wellbeing benefits are expected, NICE recommends the parallel use of an ICECAP measure but their measurement properties in this context are yet unknown. What does the paper add to existing knowledge? This is the first study exploring the psychometric properties of the EQ-5D-5L and ICECAP-A measures in the context of drug addiction. The results indicate that the ICECAP-A is a promising measure for capturing both health and broader wellbeing benefits in this context. 3 ABSTRACT Background:Measuring outcomes in economic evaluations of social care interventions is

show abstract

Section: Discussionsupporting

confidence: 78%

Section: Introductionmentioning

confidence: 99%

Measuring Health and Broader Well-Being Benefits in the Context of Opiate Dependence: The Psychometric Performance of the ICECAP-A and the EQ-5D-5L

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The difference in health utility observed in this cross-sectional comparison of MMT and non-MMT group (0.080) was similar to the estimated improvement in health utility within MMT groups over 9-month follow-up (0.076) (Tran et al, 2012e). Compared to international settings, health utility gained in Vietnam was slightly higher than what was found in the Netherlands (0.058) (Dijkgraaf et al, 2005), and comparable with findings from Canada (Nosyk et al, 2011). In the literature, trajectories of health outcomes under MMT were consistent.…”

Section: Discussionsupporting

confidence: 68%

Opioid pharmacotherapy: Treatment, regimes, constructions and control

Neale¹

2013

International Journal of Drug Policy

View full text Add to dashboard Cite

“…Furthermore, given the high proportion of opioid dependent patients with comorbid psychiatric disorders, the reduction of psychopathological symptoms is a legitimate and important goal of treatment. It is increasingly recognized that outcomes reflecting these changes, such as psychosocial symptom burden or quality of life measures, should be included in studies on the effectiveness of substance use treatment (Nosyk et al, 2011). Our findings underline the importance of these parameters in clinical practice.…”

Section: Discussionmentioning

confidence: 58%

Evaluation of medication-assisted treatment of opioid dependence—The physicians’ perspective

Vogel

Nordt

Dürsteler

et al. 2016

Drug and Alcohol Dependence

View full text Add to dashboard Cite

BACKGROUND: There is controversy about which outcome parameters should be employed to assess substance use treatment. Subjective measures of medication-assisted treatment (MAT) of opioid dependence are increasingly important. However, while patients' perspectives have been examined, the caregivers' views remain largely unknown. Here, we explore how physicians evaluate MAT, and which predictors are most relevant. METHODS: We conducted a retrospective cohort study of all MAT episodes with oral opioid agonists in the canton of Zurich between 1998 and 2013 using a case register. Termination forms of the register include a physician-completed assessment on the course of the treatment episode. Mixed model analysis was applied to determine relevant predictors. RESULTS: The analysis was based on 17,234 episodes from 7432 patients. Mean global assessment of the course of MAT was 'moderate'. The most important predictors for treatment evaluation by physicians were treatment break off as reason for termination (p<0.0001), psychological improvement throughout treatment (p<0.0001), wish for abstinence from the substitute (p<0.0001), social integration index at termination (p<0.0001), and social (p<0.0001) as well as medical (p<0.0001) improvement. The negative association of treatment break off with MAT assessment was more pronounced in semi-rural than urban areas (p<0.0001). CONCLUSION: Predictors relating to the well-being and functioning of the patient as well as the reasons underlying treatment termination appear to be more important for the treating physician's evaluation of medication-assisted treatment episodes than on-going substance use. Coming off the opioid medication plays a central role, independent of ongoing illicit substance use. Predictors relating to the well-being and functioning of the patient as well as the reasons underlying treatment termination appear to be more important for the treating physician's evaluation of medication-assisted treatment episodes than on-going substance use. Coming off the opioid medication plays a central role, independent of ongoing illicit substance use.

show abstract

Health related quality of life trajectories of patients in opioid substitution treatment

Cited by 56 publications

References 37 publications

Measuring Health and Broader Well-Being Benefits in the Context of Opiate Dependence: The Psychometric Performance of the ICECAP-A and the EQ-5D-5L

Measuring Health and Broader Well-Being Benefits in the Context of Opiate Dependence: The Psychometric Performance of the ICECAP-A and the EQ-5D-5L

Opioid pharmacotherapy: Treatment, regimes, constructions and control

Evaluation of medication-assisted treatment of opioid dependence—The physicians’ perspective

Contact Info

Product

Resources

About